Starpharma to progress R-BV drug
Market watch top headlines
MELBOURNE, April 3 AAP
April 03 2013, 6:02PM
Biotech Starpharma is considering a more advanced trial of its treatment for recurrent bacterial vaginosis (R-BV).
Starpharma said on Wednesday that a Phase II trial of VivaGel to prevent R-BV had yielded positive results.
"The results demonstrated the ability of VivaGel to inhibit BV recurrence, as was suggested by results of earlier clinical trials, and they provide strong support for the advancement to Phase III clinical trials of VivaGel for the prevention of R-BV," Starpharma said in a statement after the share market had closed.
Starpharma said the results from the Phase II trial showed a reduced overall risk of R-BV during the study in patients using VivaGel and time to first recurrence was delayed compared with a placebo.
"The commercial opportunity for recurrent BV is very attractive, with an estimated market of more than $1 billion," Starpharma chief executive Dr Jackie Fairley said.
"Following these results, we have a high degree of confidence to move this product forward into Phase III clinical trials."
Starpharma said BV was the most common vaginal infection worldwide, and the most common cause of vaginal irritation, discharge and malodour.
In the United States, BV affected an estimated one-third of the adult female population.
Shares in Starpharma last traded at $1.085.
By Trevor Chappell